O
MNTA

OrbiMed’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

OrbiMed’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,125,900
Closed -$15.7M – 152
2017
Q4 		$15.7M Sell
1,125,900
-983,168
-47% -$13.3M 0.2% 85
2017
Q3 		$39M Hold
2,109,068
– – 0.37% 70
2017
Q2 		$35.6M Hold
2,109,068
– – 0.37% 68
2017
Q1 		$28.2M Sell
2,109,068
-842,900
-29% -$13.2M 0.32% 66
2016
Q4 		$44.4M Buy
+2,951,968
New +$39M 0.57% 50

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

OrbiMed's MNTA Position: Q1 2018 in Review

OrbiMed sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2018, closing a stake of 1,125,900 shares — an estimated $15.7M sold.

OrbiMed first reported a position in MNTA in Q4 2016 and held it in 5 quarters. The position peaked at $44.4M in Q4 2016. 163 funds tracked by Wall St. Rank hold MNTA as of Q1 2018.

  • OrbiMed reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • OrbiMed sold 1,125,900 Momenta Pharmaceuticals, Inc. shares in Q1 2018, an estimated $15.7M.
  • OrbiMed first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2016 and held it in 5 quarters.
  • OrbiMed's Momenta Pharmaceuticals, Inc. position peaked at $44.4M in Q4 2016.
  • 163 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.